[HTML][HTML] Statins: is it really time to reassess benefits and risks?
AB Goldfine - New England Journal of Medicine, 2012 - Mass Medical Soc
New England Journal of Medicine, 2012•Mass Medical Soc
Statins: Is It Really Time to Reassess Benefits and Risks? | NEJM Skip to main content NEJM
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a
physician, build your knowledge, lead a health care organization, and advance your career with
NEJM Group information and services. NEJM Evidence NEW! A digital journal for innovative
original research and fresh, bold ideas in clinical trial design and clinical decision-making.
NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to accelerate the …
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a
physician, build your knowledge, lead a health care organization, and advance your career with
NEJM Group information and services. NEJM Evidence NEW! A digital journal for innovative
original research and fresh, bold ideas in clinical trial design and clinical decision-making.
NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to accelerate the …
The Food and Drug Administration has added information to statin labels regarding an effect on diabetes, noting reported increases in glycated hemoglobin and fasting serum glucose levels but adding that it believes that the cardiovascular benefits outweigh the risks.
The New England Journal Of Medicine